SHR-9839 is named as a drug or biological intervention in 6 clinical trials in our China trial register, 6 of which are recruiting. Lead sponsors include Suzhou Suncadia Biopharmaceuticals Co., Ltd. (4) and Shanghai Hengrui Pharmaceutical Co., Ltd. (2). Registered phases: Phase 1/2, Phase 1 and Phase 2. Conditions studied include Solid Tumor; Advanced Solid Tumors; Advanced Solid Tumor.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Solid Tumor | 1 |
| Advanced Solid Tumors | 1 |
| Advanced Solid Tumor | 1 |
| Advanced Esophageal Squamous Cell Carcinoma | 1 |
| Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | 1 |
| Non-small Cell Lung Cancer (NSCLC) | 1 |
| Lead sponsor | Trials |
|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 4 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 2 |
| Register | SHR-9839 trials |
|---|---|
| Clinical trials in China | 6 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SHR-9839 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SHR-9839 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.